| WB | 咨询技术 | Rat |
| IF | 咨询技术 | Rat |
| IHC | 1/50-1/100 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | ADRA1A; ADRA1C; Alpha-1A adrenergic receptor; Alpha-1A adrenoreceptor; Alpha-1A adrenoceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c |
| Entrez GeneID | 148 |
| WB Predicted band size | Calculated MW: 51 kDa; Observed MW: 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | A synthetic peptide of human alpha 1a Adrenergic Receptor |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于α1A肾上腺素受体(ADRA1A)抗体的参考文献示例(注：内容为示例性概括，非真实文献)：
---
1. **文献名称**: "Development of a Novel Monoclonal Antibody Specific for the α1A-Adrenergic Receptor"
**作者**: Smith J, et al.
**摘要**: 本研究报道了一种高特异性抗α1A-AR单克隆抗体的开发。通过重组人α1A-AR胞外域免疫小鼠，筛选出能特异性识别天然受体且不与α1B/α1D亚型交叉反应的抗体，验证其在免疫组织化学(IHC)和Western blot中的应用。
---
2. **文献名称**: "α1A-Adrenoceptor Expression in Human Prostate Tissue: A Comparative Study Using Immunohistochemistry"
**作者**: Lee H, et al.
**摘要**: 利用商业化α1A-AR抗体分析良性前列腺增生(BPH)患者与正常前列腺组织的受体表达差异，发现BPH组织中α1A-AR表达显著上调，提示其与疾病进展的潜在关联。
---
3. **文献名称**: "Functional Characterization of α1A-Adrenergic Receptor Antibodies in Cardiovascular Disease Models"
**作者**: Garcia R, et al.
**摘要**: 研究评估了α1A-AR抗体对血管平滑肌收缩的影响，发现抗体通过阻断受体活性抑制去甲肾上腺素诱导的血管收缩，为高血压的靶向治疗提供实验依据。
---
4. **文献名称**: "Subcellular Localization of α1A-Adrenergic Receptors in Neuronal Cells Using Confocal Microscopy"
**作者**: Wang Y, et al.
**摘要**: 采用亲和纯化的多克隆α1A-AR抗体，结合共聚焦显微镜技术，揭示了该受体在神经元突触前膜的高密度分布，暗示其在神经信号传递中的作用。
---
**建议**：以上为示例文献框架，实际文献需通过PubMed、Google Scholar等平台以关键词“α1A adrenergic receptor antibody”或“ADRA1A antibody”检索近年研究。
The alpha-1a adrenergic receptor (α1A-AR), a member of the G protein-coupled receptor (GPCR) superfamily, mediates physiological responses to catecholamines like epinephrine and norepinephrine. It couples primarily to Gq/11 proteins, activating phospholipase C to trigger intracellular calcium release and protein kinase C signaling. This receptor is widely expressed in vascular smooth muscle, the heart, brain, and genitourinary tract, playing key roles in blood pressure regulation, smooth muscle contraction, and neurotransmission.
Antibodies targeting the α1A-AR are critical tools for studying its expression, localization, and function. Developed using immunogenic peptide sequences from extracellular or intracellular domains, these antibodies include polyclonal and monoclonal types. They enable techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to assess receptor distribution in tissues or cultured cells. Specificity validation via knockout controls or blocking peptides is essential due to structural similarities among adrenergic receptor subtypes.
Research applications span cardiovascular diseases (e.g., hypertension), benign prostatic hyperplasia (BPH), and neurological disorders. α1A-AR antibodies also aid in evaluating receptor regulation during chronic agonist exposure and drug development, particularly for subtype-selective antagonists. Species cross-reactivity (human, rat, mouse) is common but varies by antibody design. Challenges include distinguishing α1A-AR from closely related α1B and α1D subtypes, necessitating careful experimental design. These reagents remain pivotal in elucidating adrenergic signaling mechanisms and therapeutic targeting.
×
